NewsRx Logo Login/Signup
Home Newsletters Products Library About Us Contact -- Search NewsRx

NewsRx | Free Trials
Advertisement
VerticalNews | Global Warming
Advertisement
NewsRx | Free Trials
Advertisement
----------
------------
NewsRx on Facebook
-----
Press Release Submissions
PR Login
*
*

Biotech Business Week

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Biotech Business Week

Learn More

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Buy Now



Anthrax Vaccines



Studies from Medarex, Inc. describe new findings in anthrax vaccines



January 29th, 2007

Research findings, "Prophylaxis and therapy of inhalational anthrax by a novel monoclonal antibody to protective antigen that mimics vaccine-induced immunity," are discussed in a new report. "The neutralizing antibody response to the protective antigen (PA) component of anthrax toxin elicited by approved anthrax vaccines is an accepted correlate for vaccine-mediated protection against anthrax. We reasoned that a human anti-PA monoclonal antibody (MAb) selected on the basis of superior toxin neutralization activity might provide potent protection against anthrax," scientists in the United States report.

"The fully human MAb (also referred to as MDX-1303 or Valortim) was...


Source: Biotech Business Week (2007-01-29)

NewsRx Passes
Advertisement
More Articles

Related Topics

------------------------
Security by Verisign PR Login